The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Novartis, a leading innovative medicines company, and the National Football League (NFL) announced an unprecedented partnership that names Novartis as the official first-in-category corporate ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This ...

The exclusive negotiating window for Visa, a 30-year NFL sponsor, to renew its deal with the league has expired, and the NFL ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.

Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...